Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Oct;103(4):282-9.
doi: 10.1016/S1081-1206(10)60526-1.

The atopic march: what's the evidence?

Jennifer Ker  1 , Tina V Hartert
Affiliations
Review

The atopic march: what's the evidence?

Jennifer Ker et al. Ann Allergy Asthma Immunol. 2009 Oct.

Abstract

Objective: To review and compile data from published studies that provide support for the existence of the atopic march.

Data sources: Relevant articles and references found via a PubMed search using the following keywords: atopic march, allergic march, atopic dermatitis, eczema, atopic eczema, atopy, rhinitis, wheeze, bronchiolitis, and asthma.

Study selection: All articles were reviewed and the most relevant were selected for inclusion in this review and for the compilation and graphical presentation of disease trends.

Results: Data on the prevalence of each phenotype of the atopic march confirm the temporal pattern of progression from eczema to allergic rhinitis and asthma. However, the atopic march as it is currently defined, is lacking precision, which affects its usefulness. Early events in the atopic march, such as eczema, may be more useful with more careful refinement of the phenotype into atopic and nonatopic eczema.

Conclusion: Evidence supports that the atopic march is a useful paradigm to describe the clinically observed progression of atopy in certain children. There may be more precise phenotypes of the early stages of the atopic march that may improve its utility in predicting the development of later atopic, comorbid chronic disease.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The prevalence of current eczema, allergic rhinitis, and asthma estimated from compiled data over the age span of birth to 70 years, incorporating studies from 1980 to 2008. Prevalence data used to generate these figures were from studies that used questionnaire data from developed countries, including the United States, Western Europe, and the United Kingdom.
See this image and copyright information in PMC

References

    1. Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol. 2003;112(6 suppl):S118–S127. - PubMed
    1. Coca AF, Cooke RA. On the classification of the phenomena of hypersensitiveness. J Immunol. 1923;8:163–182.
    1. Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004;113:832–836. - PubMed
    1. Wright AL. The epidemiology of the atopic child: who is at risk for what? J Allergy Clin Immunol. 2004;113(1 suppl):S2–S7. - PubMed
    1. van der Hulst AE, Klip H, Brand PL. Risk of developing asthma in young children with atopic eczema: a systematic review. J Allergy Clin Immunol. 2007;120:565–569. - PubMed

Publication types